Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$6.10+0.22 (+3.74%)
Close on Nov 13, 2026Market cap $114.13MP/E –Yield –
Trinity Biotech gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 38.6%, against 34.8% the year before. The highest annual figure on record is 47.6% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.6% | +3.7 |
| FY2024 | Dec 31, 2024 | 34.8% | +0.6 |
| FY2023 | Dec 31, 2023 | 34.2% | +6.6 |
| FY2022 | Dec 31, 2022 | 27.6% | −13.6 |
| FY2021 | Dec 31, 2021 | 41.2% | −6.4 |
| FY2020 | Dec 31, 2020 | 47.6% | +5.5 |
| FY2019 | Dec 31, 2019 | 42.2% | −0.6 |
| FY2018 | Dec 31, 2018 | 42.7% | +0.5 |
| FY2017 | Dec 31, 2017 | 42.3% | −1.4 |
| FY2016 | Dec 31, 2016 | 43.7% | −2.8 |
| FY2015 | Dec 31, 2015 | 46.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | 43.2% | – |
| Q2 FY2017 | Jun 30, 2017 | 42.5% | – |
See a number that looks wrong?